Neutrophil-To-Lymphocyte Ratio as a Prognostic Indicator in Thyroid Cancer

Objective In this study, we aimed to perform a comprehensive analysis to assess the prognostic value of neutrophil-to-lymphocyte ratio (NLR) levels in patients diagnosed with thyroid cancer. Methods We systematically searched multiple databases, including PubMed, the Cochrane Library, EMBASE, and Go...

Full description

Saved in:
Bibliographic Details
Published in:Cancer control 2024-12, Vol.31, p.10732748241309048
Main Authors: Gao, Qiangang, Quan, Mingming, Zhang, Lilong, Ran, Yanyun, Zhong, Jijun, Wang, Bin
Format: Article
Language:English
Subjects:
Disease-Free Survival
Female
Humans
Leukocytes (neutrophilic)
Lymphocyte Count
Lymphocytes
Male
Neutrophils
Patients
Prognosis
Sensitivity analysis
Thyroid cancer
Thyroid Neoplasms - blood
Thyroid Neoplasms - mortality
Thyroid Neoplasms - pathology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c316t-62e7d0910c9e148be90c2aaa9a60614dfe914f41fa6ce6a50e76476eb400d6003
container_end_page
container_issue
container_start_page 10732748241309048
container_title Cancer control
container_volume 31
creator Gao, Qiangang
Quan, Mingming
Zhang, Lilong
Ran, Yanyun
Zhong, Jijun
Wang, Bin
description Objective In this study, we aimed to perform a comprehensive analysis to assess the prognostic value of neutrophil-to-lymphocyte ratio (NLR) levels in patients diagnosed with thyroid cancer. Methods We systematically searched multiple databases, including PubMed, the Cochrane Library, EMBASE, and Google Scholar, up until March 30, 2023, to identify relevant articles. The clinical outcomes evaluated in this study included overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), and cause-specific survival (CSS). Results This analysis includes 21 articles with 5187 patients in total. The pooled results revealed that patients with high NLR levels had significantly poorer OS (HR: 2.578, 95% CI: 2.050-3.242, P < 0.001), PFS (HR: 2.143, 95% CI: 1.616-2.843, P < 0.001), DFS (HR: 1.377, 95% CI: 1.045-1.816, P = 0.023), and CSS (HR: 2.842, 95% CI: 1.334-6.053, P = 0.007). The subgroup analyses were performed based on different study regions, treatment modalities, cancer types, and NLR cut-off values, and the above conclusion remained consistent in the majority of subgroup analyses. The stability and reliability of the aforementioned results were supported by the sensitivity analysis and publication bias test. Conclusion The baseline NLR levels were useful predictors of outcomes in patients with thyroid cancer.
doi_str_mv 10.1177/10732748241309048
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_c1e0b4631dc84f3fb0272241fbdd68f1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_10732748241309048</sage_id><doaj_id>oai_doaj_org_article_c1e0b4631dc84f3fb0272241fbdd68f1</doaj_id><sourcerecordid>3149772020</sourcerecordid><originalsourceid>FETCH-LOGICAL-c316t-62e7d0910c9e148be90c2aaa9a60614dfe914f41fa6ce6a50e76476eb400d6003</originalsourceid><addsrcrecordid>eNp1kcGO0zAQhi0EYpeFB-CCInHhkmXGdu34iKoFiipAqJwjxx63qdK42Mmhb49Ll0UCcbJlf_N5PD9jLxFuEbV-i6AF17LhEgUYkM0jdo0LrmouFuZx2Zf7-gxcsWc57wE4SCGfsithlFFNw6_Zp880Tyked_1Qb2K9Ph2Ou-hOE1Xf7NTHyubKVl9T3I4xT72rVqPvnZ1iqvqx2uxOKfa-WtrRUXrOngQ7ZHpxv96w7-_vNsuP9frLh9Xy3bp2AtVUK07ag0FwhlA2HRlw3FprrAKF0gcyKIPEYJUjZRdAWkmtqJMAXgGIG7a6eH20-_aY-oNNpzbavv11ENO2tan0OlDrkKCTSqB3jQwidMA1L9MKnfeqCVhcby6uY4o_ZspTe-izo2GwI8U5twKlRiEEiIK-_gvdxzmN5adnymjNy3gLhRfKpZhzovDQIEJ7Dq39J7RS8-rePHcH8g8Vv1MqwO0FyHZLf579v_En08Ochw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3149772020</pqid></control><display><type>article</type><title>Neutrophil-To-Lymphocyte Ratio as a Prognostic Indicator in Thyroid Cancer</title><source>SAGE database</source><source>PubMed Central</source><source>ProQuest Publicly Available Content database</source><creator>Gao, Qiangang ; Quan, Mingming ; Zhang, Lilong ; Ran, Yanyun ; Zhong, Jijun ; Wang, Bin</creator><creatorcontrib>Gao, Qiangang ; Quan, Mingming ; Zhang, Lilong ; Ran, Yanyun ; Zhong, Jijun ; Wang, Bin</creatorcontrib><description>Objective In this study, we aimed to perform a comprehensive analysis to assess the prognostic value of neutrophil-to-lymphocyte ratio (NLR) levels in patients diagnosed with thyroid cancer. Methods We systematically searched multiple databases, including PubMed, the Cochrane Library, EMBASE, and Google Scholar, up until March 30, 2023, to identify relevant articles. The clinical outcomes evaluated in this study included overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), and cause-specific survival (CSS). Results This analysis includes 21 articles with 5187 patients in total. The pooled results revealed that patients with high NLR levels had significantly poorer OS (HR: 2.578, 95% CI: 2.050-3.242, P &lt; 0.001), PFS (HR: 2.143, 95% CI: 1.616-2.843, P &lt; 0.001), DFS (HR: 1.377, 95% CI: 1.045-1.816, P = 0.023), and CSS (HR: 2.842, 95% CI: 1.334-6.053, P = 0.007). The subgroup analyses were performed based on different study regions, treatment modalities, cancer types, and NLR cut-off values, and the above conclusion remained consistent in the majority of subgroup analyses. The stability and reliability of the aforementioned results were supported by the sensitivity analysis and publication bias test. Conclusion The baseline NLR levels were useful predictors of outcomes in patients with thyroid cancer.</description><identifier>ISSN: 1073-2748</identifier><identifier>ISSN: 1526-2359</identifier><identifier>EISSN: 1526-2359</identifier><identifier>DOI: 10.1177/10732748241309048</identifier><identifier>PMID: 39696882</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Disease-Free Survival ; Female ; Humans ; Leukocytes (neutrophilic) ; Lymphocyte Count ; Lymphocytes ; Male ; Neutrophils ; Patients ; Prognosis ; Sensitivity analysis ; Thyroid cancer ; Thyroid Neoplasms - blood ; Thyroid Neoplasms - mortality ; Thyroid Neoplasms - pathology</subject><ispartof>Cancer control, 2024-12, Vol.31, p.10732748241309048</ispartof><rights>The Author(s) 2024</rights><rights>The Author(s) 2024. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c316t-62e7d0910c9e148be90c2aaa9a60614dfe914f41fa6ce6a50e76476eb400d6003</cites><orcidid>0009-0009-2352-3430</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/10732748241309048$$EPDF$$P50$$Gsage$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3149772020?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>313,314,776,780,788,21942,25728,27827,27896,27898,27899,36986,36987,44563,44918,45306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39696882$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gao, Qiangang</creatorcontrib><creatorcontrib>Quan, Mingming</creatorcontrib><creatorcontrib>Zhang, Lilong</creatorcontrib><creatorcontrib>Ran, Yanyun</creatorcontrib><creatorcontrib>Zhong, Jijun</creatorcontrib><creatorcontrib>Wang, Bin</creatorcontrib><title>Neutrophil-To-Lymphocyte Ratio as a Prognostic Indicator in Thyroid Cancer</title><title>Cancer control</title><addtitle>Cancer Control</addtitle><description>Objective In this study, we aimed to perform a comprehensive analysis to assess the prognostic value of neutrophil-to-lymphocyte ratio (NLR) levels in patients diagnosed with thyroid cancer. Methods We systematically searched multiple databases, including PubMed, the Cochrane Library, EMBASE, and Google Scholar, up until March 30, 2023, to identify relevant articles. The clinical outcomes evaluated in this study included overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), and cause-specific survival (CSS). Results This analysis includes 21 articles with 5187 patients in total. The pooled results revealed that patients with high NLR levels had significantly poorer OS (HR: 2.578, 95% CI: 2.050-3.242, P &lt; 0.001), PFS (HR: 2.143, 95% CI: 1.616-2.843, P &lt; 0.001), DFS (HR: 1.377, 95% CI: 1.045-1.816, P = 0.023), and CSS (HR: 2.842, 95% CI: 1.334-6.053, P = 0.007). The subgroup analyses were performed based on different study regions, treatment modalities, cancer types, and NLR cut-off values, and the above conclusion remained consistent in the majority of subgroup analyses. The stability and reliability of the aforementioned results were supported by the sensitivity analysis and publication bias test. Conclusion The baseline NLR levels were useful predictors of outcomes in patients with thyroid cancer.</description><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Humans</subject><subject>Leukocytes (neutrophilic)</subject><subject>Lymphocyte Count</subject><subject>Lymphocytes</subject><subject>Male</subject><subject>Neutrophils</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Sensitivity analysis</subject><subject>Thyroid cancer</subject><subject>Thyroid Neoplasms - blood</subject><subject>Thyroid Neoplasms - mortality</subject><subject>Thyroid Neoplasms - pathology</subject><issn>1073-2748</issn><issn>1526-2359</issn><issn>1526-2359</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp1kcGO0zAQhi0EYpeFB-CCInHhkmXGdu34iKoFiipAqJwjxx63qdK42Mmhb49Ll0UCcbJlf_N5PD9jLxFuEbV-i6AF17LhEgUYkM0jdo0LrmouFuZx2Zf7-gxcsWc57wE4SCGfsithlFFNw6_Zp880Tyked_1Qb2K9Ph2Ou-hOE1Xf7NTHyubKVl9T3I4xT72rVqPvnZ1iqvqx2uxOKfa-WtrRUXrOngQ7ZHpxv96w7-_vNsuP9frLh9Xy3bp2AtVUK07ag0FwhlA2HRlw3FprrAKF0gcyKIPEYJUjZRdAWkmtqJMAXgGIG7a6eH20-_aY-oNNpzbavv11ENO2tan0OlDrkKCTSqB3jQwidMA1L9MKnfeqCVhcby6uY4o_ZspTe-izo2GwI8U5twKlRiEEiIK-_gvdxzmN5adnymjNy3gLhRfKpZhzovDQIEJ7Dq39J7RS8-rePHcH8g8Vv1MqwO0FyHZLf579v_En08Ochw</recordid><startdate>20241201</startdate><enddate>20241201</enddate><creator>Gao, Qiangang</creator><creator>Quan, Mingming</creator><creator>Zhang, Lilong</creator><creator>Ran, Yanyun</creator><creator>Zhong, Jijun</creator><creator>Wang, Bin</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><general>SAGE Publishing</general><scope>AFRWT</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PKEHL</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>DOA</scope><orcidid>https://orcid.org/0009-0009-2352-3430</orcidid></search><sort><creationdate>20241201</creationdate><title>Neutrophil-To-Lymphocyte Ratio as a Prognostic Indicator in Thyroid Cancer</title><author>Gao, Qiangang ; Quan, Mingming ; Zhang, Lilong ; Ran, Yanyun ; Zhong, Jijun ; Wang, Bin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c316t-62e7d0910c9e148be90c2aaa9a60614dfe914f41fa6ce6a50e76476eb400d6003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Humans</topic><topic>Leukocytes (neutrophilic)</topic><topic>Lymphocyte Count</topic><topic>Lymphocytes</topic><topic>Male</topic><topic>Neutrophils</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Sensitivity analysis</topic><topic>Thyroid cancer</topic><topic>Thyroid Neoplasms - blood</topic><topic>Thyroid Neoplasms - mortality</topic><topic>Thyroid Neoplasms - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gao, Qiangang</creatorcontrib><creatorcontrib>Quan, Mingming</creatorcontrib><creatorcontrib>Zhang, Lilong</creatorcontrib><creatorcontrib>Ran, Yanyun</creatorcontrib><creatorcontrib>Zhong, Jijun</creatorcontrib><creatorcontrib>Wang, Bin</creatorcontrib><collection>SAGE database</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Publicly Available Content database</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Directory of Open Access Journals</collection><jtitle>Cancer control</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gao, Qiangang</au><au>Quan, Mingming</au><au>Zhang, Lilong</au><au>Ran, Yanyun</au><au>Zhong, Jijun</au><au>Wang, Bin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neutrophil-To-Lymphocyte Ratio as a Prognostic Indicator in Thyroid Cancer</atitle><jtitle>Cancer control</jtitle><addtitle>Cancer Control</addtitle><date>2024-12-01</date><risdate>2024</risdate><volume>31</volume><spage>10732748241309048</spage><pages>10732748241309048-</pages><issn>1073-2748</issn><issn>1526-2359</issn><eissn>1526-2359</eissn><abstract>Objective In this study, we aimed to perform a comprehensive analysis to assess the prognostic value of neutrophil-to-lymphocyte ratio (NLR) levels in patients diagnosed with thyroid cancer. Methods We systematically searched multiple databases, including PubMed, the Cochrane Library, EMBASE, and Google Scholar, up until March 30, 2023, to identify relevant articles. The clinical outcomes evaluated in this study included overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), and cause-specific survival (CSS). Results This analysis includes 21 articles with 5187 patients in total. The pooled results revealed that patients with high NLR levels had significantly poorer OS (HR: 2.578, 95% CI: 2.050-3.242, P &lt; 0.001), PFS (HR: 2.143, 95% CI: 1.616-2.843, P &lt; 0.001), DFS (HR: 1.377, 95% CI: 1.045-1.816, P = 0.023), and CSS (HR: 2.842, 95% CI: 1.334-6.053, P = 0.007). The subgroup analyses were performed based on different study regions, treatment modalities, cancer types, and NLR cut-off values, and the above conclusion remained consistent in the majority of subgroup analyses. The stability and reliability of the aforementioned results were supported by the sensitivity analysis and publication bias test. Conclusion The baseline NLR levels were useful predictors of outcomes in patients with thyroid cancer.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>39696882</pmid><doi>10.1177/10732748241309048</doi><orcidid>https://orcid.org/0009-0009-2352-3430</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1073-2748
ispartof Cancer control, 2024-12, Vol.31, p.10732748241309048
issn 1073-2748
1526-2359
1526-2359
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_c1e0b4631dc84f3fb0272241fbdd68f1
source SAGE database; PubMed Central; ProQuest Publicly Available Content database
subjects Disease-Free Survival
Female
Humans
Leukocytes (neutrophilic)
Lymphocyte Count
Lymphocytes
Male
Neutrophils
Patients
Prognosis
Sensitivity analysis
Thyroid cancer
Thyroid Neoplasms - blood
Thyroid Neoplasms - mortality
Thyroid Neoplasms - pathology
title Neutrophil-To-Lymphocyte Ratio as a Prognostic Indicator in Thyroid Cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-27T15%3A20%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neutrophil-To-Lymphocyte%20Ratio%20as%20a%20Prognostic%20Indicator%20in%20Thyroid%20Cancer&rft.jtitle=Cancer%20control&rft.au=Gao,%20Qiangang&rft.date=2024-12-01&rft.volume=31&rft.spage=10732748241309048&rft.pages=10732748241309048-&rft.issn=1073-2748&rft.eissn=1526-2359&rft_id=info:doi/10.1177/10732748241309048&rft_dat=%3Cproquest_doaj_%3E3149772020%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c316t-62e7d0910c9e148be90c2aaa9a60614dfe914f41fa6ce6a50e76476eb400d6003%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3149772020&rft_id=info:pmid/39696882&rft_sage_id=10.1177_10732748241309048&rfr_iscdi=true